US EditionBayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer aims to resolve about 67,000 claims alleging Roundup exposure caused non-Hodgkin's lymphoma with a 21-year compensation program, pending Supreme Court review.
- Announcing a long-term compensation program, Bayer proposed a $10.5 billion settlement to resolve current and future Roundup cancer lawsuits, covering plaintiffs exposed before Feb. 17, 2026.
- After acquiring Monsanto for $66 billion, Bayer inherited about 67,000 outstanding Roundup claims and faces pressure as the U.S. Supreme Court reviews a key appeal.
- The settlement would fund a common claims program over 21 years, managed by a professional claims administrator; Bayer said, "The proposed class settlement differs markedly from the prior class settlement put forth by the company in 2020."
- Bayer shares pushed higher in Frankfurt after the announcement, rising as much as 7.9% and setting aside 10.5 billion euros for litigation, with about five billion euros expected payouts for 2026, delaying results from February 25 to March 4.
- A favorable Supreme Court decision would largely foreclose state label-based claims, and the source said the case remains critical while CEO Bill Anderson weighs stopping glyphosate production.
26 Articles
26 Articles
ABC FOX Montana
Bayer proposes class settlement for weedkiller cancer claims
German agrochemical giant Bayer said Tuesday its subsidiary Monsanto had proposed a class settlement of up to $7.25 billion to settle claims that the Roundup weedkiller causes blood cancer, potentially drawing a line under years of costly litigation.
OC Register
Insurance JournalBayer to make $10.5 billion push to settle Roundup cases
The settlement would resolve current and future cancer lawsuits over its top-selling weedkiller.
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anderson said on Tuesday.
Bayer Moves Forward with Settlement in Roundup Case
Bayer is advancing a U.S. class settlement to address claims that its Roundup weedkiller causes non-Hodgkin lymphoma. CEO Bill Anderson highlights the settlement's significance to its Supreme Court case, aiming to minimize legal risks.
Coverage Details
Bias Distribution
- 81% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
